Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MSC072
MIFTS: 53

Muscle Cancer

Categories: Cancer diseases, Muscle diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Muscle Cancer

About this section

MalaCards integrated aliases for Muscle Cancer:

Name: Muscle Cancer 12 55 15
Myosarcoma 12 55 44 73
Malignant Neoplasm of Muscle 12 73
Malignant Tumor of the Muscle 12
Malignant Tumor of Muscle 12
Myomatous Neoplasm 73
Muscle Neoplasms 44

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:4045
ICD10 33 C49
NCIt 50 C4883
Sources

Summaries for Muscle Cancer

About this section
Disease Ontology : 12 A musculoskeletal system cancer that is located in muscle.

MalaCards based summary : Muscle Cancer, also known as myosarcoma, is related to skeletal muscle cancer and leiomyosarcoma, and has symptoms including muscle cramp, muscle rigidity and muscle spasticity. An important gene associated with Muscle Cancer is PAX3 (Paired Box 3), and among its related pathways/superpathways are Endometrial cancer and ErbB signaling pathway. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include muscle, bone and nk cells, and related phenotypes are cellular and growth/size/body region

Wikipedia : 76 A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is... more...

Sources

Related Diseases for Muscle Cancer

About this section

Diseases related to Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 skeletal muscle cancer 31.4 EWSR1 FOXO1 KIDINS220 MB MYOD1 MYOG
2 leiomyosarcoma 29.8 DES KIT MB MDM2 MYOG PGR
3 rhabdomyosarcoma 29.3 DES EWSR1 FOXO1 MB MDM2 MYOD1
4 myoma 11.4
5 lymphangiomatosis 11.0 DES PGR
6 endometrium carcinoma in situ 11.0 PGR TP53
7 ovarian fibrothecoma 11.0 DES KIT
8 prostate embryonal rhabdomyosarcoma 11.0 KIT MYOD1
9 vestibular gland benign neoplasm 11.0 PGR TP53
10 giant cell myocarditis 11.0 DES MB
11 bartholin's gland adenoma 11.0 PGR TP53
12 ectomesenchymoma 10.9 DES PAX3
13 cervical polyp 10.9 DES MYOD1
14 orbit rhabdomyosarcoma 10.9 MB MYOG
15 malignant triton tumor 10.9 DES MB
16 epulis 10.9 DES PGR
17 spindle cell rhabdomyosarcoma 10.8 DES MB MYOD1
18 perivascular epithelioid cell tumor 10.8 DES KIT PGR
19 vulvar benign neoplasm 10.8 CALD1 PGR
20 testicular gonadoblastoma 10.8 KIT WT1
21 vulvar leiomyoma 10.8 CALD1 PGR
22 cerebellar angioblastoma 10.8 TP53 WT1
23 smooth muscle tumor 10.8 DES KIT PGR
24 ring chromosome 7 10.8 MDM2 TP53
25 zika virus infection 10.8 MDM2 TP53
26 breast malignant phyllodes tumor 10.8 PGR TP53
27 angiomyolipoma 10.8 DES KIT PGR
28 spindle cell lipoma 10.8 DES FOXO1 MDM2
29 olfactory groove meningioma 10.8 PGR TP53
30 prostate stromal sarcoma 10.8 CD34 PGR
31 uterine body mixed cancer 10.8 KIT PGR TP53
32 prostate rhabdomyosarcoma 10.7 KIT MYOD1
33 endosalpingiosis 10.7 PGR WT1
34 esophagus sarcoma 10.7 CREB3L2 KIT
35 central nervous system mesenchymal non-meningothelial tumor 10.7 FOXO1 MYOD1 PAX3 PAX7
36 gallbladder leiomyoma 10.7 CD34 KIT
37 lung leiomyosarcoma 10.7 CD34 KIT
38 malignant fibroxanthoma 10.7 DES MDM2 MYOD1
39 cribriform carcinoma 10.7 KIT PGR
40 sarcomatosis 10.7 EWSR1 WT1
41 lung combined type small cell carcinoma 10.7 CALD1 MYOG
42 trigonitis 10.7 CD34 PGR
43 rhabdoid cancer 10.7 DES MYOD1 WT1
44 actinic cheilitis 10.7 MDM2 TP53
45 liver leiomyoma 10.7 CD34 KIT
46 vulvar dystrophy 10.7 CD34 PGR
47 botryoid rhabdomyosarcoma 10.7 DES MB MYOD1 PAX3
48 dedifferentiated liposarcoma 10.7 DES MDM2 TP53
49 lung meningioma 10.7 CD34 PGR
50 female reproductive endometrioid cancer 10.7 PGR TP53 WT1

Graphical network of the top 20 diseases related to Muscle Cancer:



Diseases related to Muscle Cancer
Sources

Symptoms & Phenotypes for Muscle Cancer

About this section

UMLS symptoms related to Muscle Cancer:


muscle cramp, muscle rigidity, muscle spasticity, myoclonus, torticollis, muscle weakness, myalgia

MGI Mouse Phenotypes related to Muscle Cancer:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 MDM2 MB KIT FOXO1 CD34 KIDINS220
2 growth/size/body region MP:0005378 10.34 MYOG MDM2 PAX3 MYOD1 MB KIT
3 cardiovascular system MP:0005385 10.32 MDM2 PAX3 MYOD1 MB KIT FOXO1
4 homeostasis/metabolism MP:0005376 10.31 MYOG MDM2 MYOD1 MB DES KIT
5 mortality/aging MP:0010768 10.31 MYOG MDM2 PAX3 MB MYOD1 FOXO1
6 hematopoietic system MP:0005397 10.29 MDM2 PAX3 MB KIT FOXO1 CD34
7 embryo MP:0005380 10.24 MYOG MDM2 PAX3 MB FOXO1 KIT
8 muscle MP:0005369 10.18 MDM2 PAX3 MYOD1 MYOG FOXO1 MB
9 craniofacial MP:0005382 10.16 MDM2 PAX3 KIT FOXO1 CREB3L2 TFE3
10 integument MP:0010771 10.13 MYOG MDM2 KIT FOXO1 CD34 TFE3
11 digestive/alimentary MP:0005381 10.09 MDM2 KIT FOXO1 CREB3L2 PAX7 PAX3
12 neoplasm MP:0002006 10.07 MDM2 PAX3 MYOD1 FOXO1 CD34 KIT
13 no phenotypic analysis MP:0003012 10.06 MYOG MDM2 PAX3 MYOD1 FOXO1 KIDINS220
14 limbs/digits/tail MP:0005371 10 MDM2 KIT FOXO1 CREB3L2 PGR PAX3
15 normal MP:0002873 10 MYOG MDM2 PAX3 MYOD1 FOXO1 KIT
16 respiratory system MP:0005388 9.56 MYOG MYOD1 MB KIT PAX7 PAX3
17 pigmentation MP:0001186 9.55 MDM2 KIT TFE3 PAX3 TP53
18 skeleton MP:0005390 9.36 MYOG MDM2 PAX3 MYOD1 FOXO1 CREB3L2
Sources

Drugs & Therapeutics for Muscle Cancer

About this section

Drugs for Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
5 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
7 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
12
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 2019 457193
13
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
14
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
15
Morphine Approved, Investigational Phase 3,Phase 1,Phase 2 57-27-2 5288826
16
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
17
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
18
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
19
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
20
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
22
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
23
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
24
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
25
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
26
Idarubicin Approved Phase 3 58957-92-9 42890
27
Mesna Approved, Investigational Phase 3,Phase 2,Not Applicable 3375-50-6 598
28
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
29 Trofosfamide Investigational Phase 3 22089-22-1
30 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
33 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
34
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
35 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
36 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
37 Antifungal Agents Phase 3,Phase 2,Phase 1
38 Bone Density Conservation Agents Phase 3,Phase 1
39 Calcium, Dietary Phase 3
40 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
41
Vinblastine Approved Phase 2 865-21-4 13342 241903
42
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
43
Melphalan Approved Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
44
Bevacizumab Approved, Investigational Phase 2 216974-75-3
45
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
46
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
47
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
48
Fludarabine Approved Phase 1, Phase 2,Phase 2 21679-14-1, 75607-67-9 30751
49
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
50
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 160)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
3 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
4 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
5 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
6 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
7 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
8 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
9 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Recruiting NCT02567435 Phase 3 Cyclophosphamide;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
10 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Active, not recruiting NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
11 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Active, not recruiting NCT00075582 Phase 3 dactinomycin;cyclophosphamide;vincristine sulfate
12 Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood Terminated NCT00162695 Phase 3 Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide
13 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas Unknown status NCT01216839 Phase 2 Everolimus
14 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245141 Phase 2 cyclophosphamide;vincristine sulfate
15 Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245089 Phase 2 cyclophosphamide;vincristine sulfate
16 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
17 Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg Completed NCT00019968 Phase 2 melphalan;tumor necrosis factor
18 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
19 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Completed NCT01055314 Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Irinotecan Hydrochloride;Temozolomide;Vincristine Sulfate Liposome
20 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
21 Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma Completed NCT00055939 Phase 2 exatecan mesylate
22 Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma Completed NCT00025363 Phase 2 vincristine sulfate;irinotecan hydrochloride;cyclophosphamide;doxorubicin hydrochloride;ifosfamide;etoposide;tirapazamine
23 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
24 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
25 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
26 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
27 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
28 NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT01386619 Phase 1, Phase 2
29 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
30 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2 LDE225
31 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Completed NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
32 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
33 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
34 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
35 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
36 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
37 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
38 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2 indinavir sulfate
39 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2 EF-1 Peptide;EF-2 Peptide;PXFK Peptide;E7 Peptide;IL-2;IL-4;GM-CSF;CD40 Ligand
40 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Completed NCT00309907 Phase 2 methylprednisolone
41 Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy Completed NCT00187109 Phase 1, Phase 2 Recombinant Human Thrombopoietin
42 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
43 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
44 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
45 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
46 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
47 Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma Recruiting NCT03041701 Phase 1, Phase 2 Dasatinib;Ganitumab
48 Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy Recruiting NCT01871766 Phase 2 Vincristine;Dactinomycin;Cyclophosphamide;Bevacizumab;Sorafenib;Myeloid Growth Factor;Irinotecan;Ifosfamide;Etoposide;Etoposide Phosphate;Doxorubicin;Dexrazoxane;^1^1C-methionine
49 Proton RT for the Treatment of Pediatric Rhabdomyosarcoma Recruiting NCT00592592 Phase 2
50 Trial of Afatinib in Pediatric Tumours Recruiting NCT02372006 Phase 1, Phase 2 afatinib

Search NIH Clinical Center for Muscle Cancer

Cochrane evidence based reviews: myosarcoma

Sources

Genetic Tests for Muscle Cancer

About this section
Sources

Anatomical Context for Muscle Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Muscle Cancer:

19
Muscle

MalaCards organs/tissues related to Muscle Cancer:

41
Bone, Nk Cells, Bone Marrow, Myeloid, Liver, T Cells, Testes
Sources

Publications for Muscle Cancer

About this section

Articles related to Muscle Cancer:

# Title Authors Year
1
Cytotoxicity Studies of the Extracts, Fractions, and Isolated Compound of Pseudocedrela kotschyi on Cervical Cancer (HeLa), Breast Cancer (MCF-7) and Skeletal Muscle Cancer (RD) Cells. ( 28250653 )
2017
2
YAPping about differentiation therapy in muscle cancer. ( 25117705 )
2014
3
The not-so-skinny on muscle cancer. ( 23079652 )
2012
4
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. ( 20193046 )
2010
5
A new model for muscle cancer. ( 17585343 )
2007
Sources

Variations for Muscle Cancer

About this section
Sources

Expression for Muscle Cancer

About this section
Search GEO for disease gene expression data for Muscle Cancer.
Sources

Pathways for Muscle Cancer

About this section

Pathways related to Muscle Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.58 CREB3L2 FOXO1 KIT MDM2 TP53
2
ErbB signaling pathway 1 37
Show member pathways
 12.2 FOXO1 MDM2 TFE3 TP53
3
AKT Signaling Pathway 67
11.78 CREB3L2 FOXO1 MDM2 TP53
4
Transcriptional misregulation in cancer 37
11.55 ASPSCR1 EWSR1 FOXO1 MDM2 PAX3 PAX7
5
C-MYB transcription factor network 1
11.47 CD34 KIT MYOD1
6
Regulation of nuclear SMAD2/3 signaling 1
11.43 FOXO1 MYOD1 TFE3
7
Regulation of retinoblastoma protein 1
11.18 MDM2 MYOD1 PAX3
8
Copper homeostasis 1
11.06 FOXO1 MDM2 TP53
9
Signaling events mediated by HDAC Class III 1
10.72 FOXO1 MYOD1 TP53
Sources

GO Terms for Muscle Cancer

About this section

Cellular components related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 ASPSCR1 CREB3L2 DES EWSR1 FOXO1 MDM2
2 nucleoplasm GO:0005654 9.36 ASPSCR1 CREB3L2 FOXO1 MDM2 MYOD1 MYOG

Biological processes related to Muscle Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 transcription by RNA polymerase II GO:0006366 9.91 CREB3L2 MYOD1 PAX3 TFE3 TP53 WT1
2 transcription, DNA-templated GO:0006351 9.9 CREB3L2 EWSR1 FOXO1 MYOD1 MYOG PAX3
3 negative regulation of apoptotic process GO:0043066 9.88 FOXO1 KIT MDM2 PAX7 TP53 WT1
4 skeletal muscle tissue development GO:0007519 9.63 MYOD1 MYOG PAX7
5 muscle organ development GO:0007517 9.62 MYOD1 MYOG PAX3 PAX7
6 positive regulation of transcription, DNA-templated GO:0045893 9.56 CREB3L2 FOXO1 MYOD1 MYOG PAX3 TFE3
7 myotube differentiation GO:0014902 9.54 MYOD1 MYOG
8 positive regulation of skeletal muscle fiber development GO:0048743 9.51 MYOD1 MYOG
9 paracrine signaling GO:0038001 9.49 CD34 PGR
10 muscle cell fate commitment GO:0042693 9.48 MYOD1 MYOG
11 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
12 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7
13 multicellular organism development GO:0007275 10.07 CREB3L2 KIT MYOD1 MYOG PAX3 PAX7
14 regulation of transcription, DNA-templated GO:0006355 10 CREB3L2 EWSR1 FOXO1 MYOD1 MYOG PAX3

Molecular functions related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.8 MYOD1 MYOG PGR TFE3 TP53
2 transcription regulatory region DNA binding GO:0044212 9.73 CREB3L2 TFE3 TP53 WT1
3 sequence-specific DNA binding GO:0043565 9.7 FOXO1 MYOD1 MYOG PAX3 PAX7 PGR
4 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding GO:0001228 9.67 CREB3L2 MYOD1 MYOG TP53
5 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.65 CREB3L2 MYOG PGR TFE3 WT1
6 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.65 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7
7 DNA binding transcription factor activity GO:0003700 9.32 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7
8 DNA binding GO:0003677 10.02 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7
Sources

Sources for Muscle Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....